What is the N‑acetylcysteine (NAC) infusion protocol for acetaminophen poisoning after 24 hours?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 30, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

NAC Infusion Protocol for Acetaminophen Poisoning After 24 Hours

Administer NAC immediately when patients present more than 24 hours after acetaminophen ingestion, using the standard 21-hour intravenous protocol (300 mg/kg total dose), and continue treatment beyond 21 hours if hepatotoxicity is present or acetaminophen remains detectable.

Immediate Management Approach

When a patient presents >24 hours post-ingestion:

  • Start NAC immediately without waiting for laboratory results 1
  • The Rumack-Matthew nomogram does NOT apply to presentations beyond 24 hours 2, 1
  • Do not delay treatment to obtain acetaminophen levels—initiate the loading dose first

Standard IV NAC Protocol

The FDA-approved regimen consists of three doses over 21 hours 1:

Loading Dose: 150 mg/kg IV over 1 hour
Second Dose: 50 mg/kg IV over 4 hours
Third Dose: 100 mg/kg IV over 16 hours
Total: 300 mg/kg over 21 hours

Critical Dilution Requirements

NAC is hyperosmolar (2600 mOsmol/L) and must be diluted in sterile water, 0.45% sodium chloride, or 5% dextrose before administration 1.

Extending Treatment Beyond 21 Hours

This is the crucial decision point for late presentations. Continue NAC infusion (at 100 mg/kg over 16 hours, repeating as needed) if ANY of the following persist 1:

  • Detectable serum acetaminophen concentration
  • AST/ALT continue rising or remain elevated >1000 IU/L
  • INR remains elevated
  • Clinical evidence of hepatotoxicity or hepatic encephalopathy

Evidence for Late Treatment Efficacy

While NAC efficacy diminishes after 8 hours, it should never be withheld in late presentations 1. Historical data shows:

  • Patients treated 10-24 hours post-ingestion: 26-53% developed severe hepatotoxicity (vs. 58% with supportive care alone) 2
  • Patients treated 16-24 hours: 41-62% developed hepatotoxicity, but mortality was reduced 2, 3
  • Even at 72 hours post-ingestion, high-dose IV NAC can reverse hepatic failure 4

The key principle: NAC does not worsen outcomes and may provide benefit even in established hepatotoxicity 1.

Monitoring Requirements

Obtain baseline and serial measurements every 8-12 hours 1:

  • AST, ALT, bilirubin
  • INR
  • Creatinine, BUN
  • Electrolytes, glucose
  • Acetaminophen concentration (to guide continuation decisions)

Alternative Protocols for Late Presentations

Some evidence supports extended protocols for late/severe cases:

  • 48-hour protocol: 140 mg/kg loading, then 70 mg/kg every 4 hours for 12 doses (total 300 mg/kg over 48 hours) showed 18.1% hepatotoxicity rate with only one death 5, 6
  • This delivers higher total NAC dose and may be superior when treatment is delayed 5, 3

Common Pitfalls to Avoid

  1. Do not wait for acetaminophen levels before starting NAC in late presentations—the reported ingestion time may be inaccurate 1

  2. Do not stop at 21 hours automatically—assess stopping criteria first. Many late presenters require extended treatment 1, 7

  3. Do not use the nomogram for presentations >24 hours, repeated supratherapeutic ingestions, or extended-release formulations 2, 1

  4. Watch for hypersensitivity reactions (28.9% incidence), especially during loading dose—most are mild (flushing, urticaria) and do not require discontinuation 5. If serious reactions occur, stop infusion, treat reaction, then carefully restart 1

  5. Adjust for fluid overload risk in patients <40 kg or those requiring fluid restriction 1

Hepatic Failure Management

For patients with established hepatic failure thought to be acetaminophen-related, continue NAC indefinitely until recovery or transplant 2. Early hepatology/transplant consultation is essential for:

  • INR >2.0 despite NAC
  • Rising creatinine
  • Hepatic encephalopathy
  • Lactate >3.5 mmol/L after fluid resuscitation

The evidence strongly supports that NAC provides benefit even in fulminant hepatic failure, with case reports showing reversal of failure with extended high-dose IV NAC 4.

222211154367

Related Questions

What is the recommended N‑acetylcysteine (NAC) dosing regimen for a 50‑kg patient with acetaminophen overdose?
What is the recommended intravenous N‑acetylcysteine (NAC) regimen for a 50‑kg patient with paracetamol (acetaminophen) poisoning?
What is the recommended N‑acetylcysteine (NAC) infusion regimen for acetaminophen (paracetamol) overdose?
How should I manage a patient with acetaminophen overdose, including indications for N‑acetylcysteine (NAC), dosing protocols (intravenous 21‑hour regimen or oral regimen), use of activated charcoal, and monitoring of hepatic and coagulation parameters?
What is the recommended N‑acetylcysteine dosing regimen for acetaminophen (paracetamol) overdose in adults and children?
What are the detailed diagnostic criteria, recommended investigations, stepwise pharmacologic management with dosing, and potential complications of hypertension?
How should I evaluate and manage swelling in my right leg in a patient receiving trastuzumab emtansine (T-DM1)?
How does single-agent oral antibiotic suppressive therapy work for knee prosthetic joint infections after definitive surgical management?
Can nalbuphine (Nubain) and perampanel, when administered together, cause a synergistic bradycardic effect?
Can a transjugular intrahepatic portosystemic shunt (TIPS) be performed in patients who are dyspneic?
What is the recommended dosing schedule for spironolactone in a patient with chronic heart failure and reduced left‑ventricular ejection fraction who is already on an ACE inhibitor (or angiotensin receptor blocker) and a beta‑blocker, with normal potassium levels and adequate renal function?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.